Tiazofurin: A new antitumor agent - Investigational New Drugs

Tiazofurin is an interesting drug now entering Phase I trials, with marked preclinical antitumor activity against P388 and L1210 leukemias, and the Lewis lung carcinoma. Schedule dependency favoring frequent administration has been noted.

The drug has a novel mechanism of action, being metabolized to an inhibitory cofactor of inosine monophosphate dehydrogenase.

Tiazofurin is widely distributed after i.v. administration exhibiting a triphasic pattern of plasma decay, with a terminal half-life of 3–16 h in the three species studied. Approximately 90% of the drug was excreted unchanged in the urine within 24 h. A significant potential for the slower release of intracellularly retained drug exists.

Anticipated organ toxicities based on the studies described include myelotoxicity, hepatotoxicity and nephrotoxicity. These were mild and reversible at lower doses, and were not seen at levels corresponding to the starting doses in man. A potential for hyperuricemia exists; this should be easily controllable by the use of allopurinol, without compromising the drug's antitumor effect.

Phase I trials under the sponsorship of the NCI are underway in a number of institutions.

1. Witkowski JT, Robins RK, Sidwell RW, Simon LN: Design, synthesis, and broad spectrum antiviral activity of 1-β-D- ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem 15:1150–1154, 1972

   Google Scholar 

2. Newman H, Vodinelich L, Potter CW: The effects of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) on the transplanted tumours of animals. Eur J Cancer 13:821–830, 1977

   Google Scholar 

3. Harris S, Robins RK: In RA Smith and W Kirkpatrick (eds): Ribavirin. A Broad Spectrum Antiviral Agent. Academic Press, New York, 1980

   Google Scholar 

4. Clinical Brochure for Tiazofurin, December, 1982. Division of Cancer Treatment, National Cancer Institute.

5. Robins RK, Srivastava PC, Narayanan VL, Plowman J, Paull KD: 2-β-D-Ribofuranosylthiazole-4-carboxamide, a novel potential antitumor agent for lung tumors and metastases. J Med Chem 25:107–108, 1982

   Google Scholar 

6. Jayaram HN, Dion RL, Glazer RI, Johns DG, Robins RK, Srivastava PC, Cooney DA: Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-β-D-ribofuranosylthiazole-4-carboxamide (NSC 286193). Biochem Pharmacol 31:2371–2380, 1982

   Google Scholar 

7. Jayaram HN, Smith AL, Glazer RI, Johns DG, Cooney DA: Studies on the mechanism of action of 2-β-D-ribofuranosylthiazole-4-carboxamide (NSC-286193) II. Relationship between dose level and biochemical effects in P388 leukemia in vivo. Biochem Pharmacol 31:3839–3845, 1982

   Google Scholar 

8. Cooney DA, Jayaram HN, Gebeyehu G, Betts CR, Kelley JA, Marquez VE, Johns DG: The conversion of 2-β-D- ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties. Biochem Pharmacol 31:2133–2136, 1982

   Google Scholar 

9. Cooney DA, Jayaram HN, Glazer RI, Kelley JA, Marquez VE, Gebeyehu G, Cott AC, Zwelling L, Johns DG: Studies on the mechanism of action of tiazofurin metabolism to an analog of NAD with potent IMP dehydrogenase-inhibitory activity. In G Weber (ed): Advances in Enzyme Regulation. Pergamon Press, New York, 1983, pp 271–303

   Google Scholar 

10. Gebeyehu G, Marquez VE, Kelley JA, Cooney DA, Jayaram HN, Johns DG: Synthesis of thiazole-4-carboxamideadenine dinucleotide (TAD). A powerful inhibitor of IMP dehydrogenase. J Med Chem 26:922–925, 1983

    Google Scholar 

11. Jayaram HN, Cooney DA, Glazer RI, Dion RL, Johns DG: Mechanism of resistance to the oncolytic C-nucleoside 2-β- D-ribofuranosylthiazole-4-carboxamide (NSC-286193). Biochem Pharmacol 31:2557–2560, 1982

    Google Scholar 

12. Kuttan R, Robins RK, Saunders PP: Inhibition of inosinate dehydrogenase by metabolites of 2-β-D-ribofuranosylthiazole-4-carboxamide. Biochem Biophys Res Commun 107:862–868, 1982

    Google Scholar 

13. Earle MF, Glazer RI: Activity and metabolism of 2-β-D-ribofuranosylthiazole-4-carboxamide in human lymphoid tumor cells in culture. Cancer Res 43:133–137, 1983

    Google Scholar 

14. Ahluwalia GS, Jayaram HN, Plowman JP, Cooney DA, Johns DG: Studies on the mechanism of action of 2-β-D-ribofuranosylthiazole-4-carboxamide V. Factors governing the response of murine tumors to tiazofurin. Manuscript in preparation, 1983

15. Carney DN, Ahluwalia GS, Jayaram HN, Cooney DA, Minna JD, Johns DG: Biochemical correlates of clonal growth inhibition in human lung tumor cell lines by tiazofurin. Clin Res 31:507A, 1983

    Google Scholar 

16. Arnold ST, Jayaram HN, Harper GR, Litterest CL, Malspeis L, DeSouza JV, Staubus AE, Ahluwalia GS, Wilson YA, Cooney DA, Johns DG: The disposition and metabolism of tiazofurin in rodents, rabbits and dogs. Manuscript in preparation, 1983

17. Data on file, Developmental Therapeutics Program, DCT, NCI, 1982

Download references

Authors and Affiliations

1. Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, 20205, Bethesda, MD, U.S.A.

   Peter J. O'Dwyer, D. Dale Shoemaker & Silvia Marsoni

2. Laboratory of Medicinal Chemistry and Pharmacology, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, 20205, Bethesda, MD, U.S.A.

   Hiremagalur N. Jayaram, David G. Johns & David A. Cooney

3. The Ohio State University Cancer Center, 500 W. 12th Avenue, 43210, Columbus, OH, U.S.A.

   Louis Malspeis

4. Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, 20205, Bethesda, MD, U.S.A.

   Jacqueline Plowman, J. Paul Davignon & Ruth D. Davis

Cite this article

O'Dwyer, P.J., Shoemaker, D.D., Jayaram, H.N. et al. Tiazofurin: A new antitumor agent. Invest New Drugs 2, 79–84 (1984). https://doi.org/10.1007/BF00173791

Download citation

• Issue Date: March 1984

• DOI: https://doi.org/10.1007/BF00173791

Key words